DHR2 Antibody

What is the DHR2 domain and its significance in DOCK proteins?

The DHR2 domain is a catalytic region of approximately 450 residues situated within the C-terminal region of DOCK proteins (DOCK DHR2). This domain plays a crucial role in the guanine nucleotide exchange factor (GEF) activity of DOCK proteins, particularly DOCK1 and DOCK2, which are specific for RAC and require ELMO (engulfment and cell motility) proteins for proper function . The DHR2 domain is structurally organized into multiple lobes (A, B, and C) that participate in protein dimerization and interaction with RAC1, making it a critical target for studying cell migration, immune responses, and related signaling pathways . Understanding the structure-function relationship of DHR2 requires specific antibodies that can recognize this domain without cross-reactivity to other protein regions.

How should researchers select appropriate DHR2 antibodies for their experiments?

When selecting DHR2 antibodies, researchers should consider several key factors to ensure experimental success:

• Epitope specificity: Choose antibodies raised against specific regions of the DHR2 domain that are accessible in the native protein conformation.

• Validated applications: Verify that the antibody has been validated for your intended application (WB, IP, IHC) with published evidence of specificity.

• Species reactivity: Ensure compatibility with your experimental model system (human, mouse, etc.).

• Clone type: Consider whether polyclonal or monoclonal antibodies are more appropriate for your research questions.

• Validation methods: Look for antibodies validated using knockout/knockdown controls to confirm specificity.

Researchers should request validation data from manufacturers and review published literature where similar antibodies have been successfully employed. Additionally, preliminary testing with positive control samples containing known DHR2-domain proteins is strongly recommended to confirm reactivity before proceeding to experimental samples.

What experimental controls are essential when working with DHR2 antibodies?

These controls are particularly important when working with DHR2 antibodies due to the structural similarities between different DOCK family proteins. Without proper controls, cross-reactivity could lead to misinterpretation of experimental results, especially in complex tissue samples where multiple DOCK proteins may be expressed simultaneously.

How can DHR2 antibodies be optimized for studying DOCK-ELMO complex formation?

The DOCK2-ELMO1 complex adopts different conformational states, including a closed auto-inhibited conformation and an active open state that exposes binding sites for RAC1 on DOCK2 DHR2 . When studying these interactions, researchers should consider:

• Epitope accessibility: Select antibodies targeting DHR2 epitopes that remain accessible in both conformational states or explicitly choose conformation-specific antibodies.

• Co-immunoprecipitation optimization: Use mild detergents (0.5-1% NP-40 or Triton X-100) to preserve protein-protein interactions during lysis.

• Crosslinking approaches: Apply membrane-permeable crosslinkers before cell lysis to stabilize transient DOCK-ELMO interactions.

• Antibody conjugation strategies: Consider directly conjugating DHR2 antibodies to minimize interference with complex formation during immunoprecipitation.

• Native PAGE conditions: Develop non-denaturing conditions that preserve the DOCK-ELMO complex integrity while allowing antibody detection.

For advanced studies of conformational changes, researchers might employ a combination of conformation-specific DHR2 antibodies in proximity ligation assays or FRET-based approaches to monitor the transition between closed and open states in cellular contexts .

What methodological approaches can address the challenges in characterizing DHR2-RAC1 interactions?

The DHR2 domain interacts with RAC1 through its B and C lobes, while dimerization occurs through the A lobe . Studying these interactions presents several challenges that can be addressed through specialized approaches:

• Temporal resolution: Use rapid immunoprecipitation techniques with pre-crosslinked complexes to capture transient DHR2-RAC1 interactions.

• Spatial resolution: Employ super-resolution microscopy with fluorescently-labeled DHR2 antibodies to visualize interaction domains within cells.

• Nucleotide-state specificity: Develop protocols that distinguish between DHR2 interactions with GDP-bound versus GTP-bound RAC1 using nucleotide-state specific antibodies.

• Mutational analysis: Combine site-directed mutagenesis of key DHR2 residues with antibody detection to map interaction surfaces.

• In vitro reconstitution: Use purified components with DHR2 antibodies to detect conformational changes during nucleotide exchange reactions.

These methodological approaches can help researchers delineate the mechanistic details of how the DHR2 domain facilitates RAC1 activation and identify potential regulatory sites that could be targeted for therapeutic intervention in diseases involving dysregulated RAC signaling.

What are the optimized protocols for using DHR2 antibodies in Western blot analysis?

For successful Western blot detection of DHR2-containing proteins, researchers should follow these methodological guidelines:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors for cell lysis

  • Sonicate briefly (3 × 10s pulses) to shear DNA and reduce sample viscosity

  • Centrifuge at 14,000g for 15 minutes at 4°C to remove insoluble material

• SDS-PAGE conditions:

  • Use 8-10% polyacrylamide gels to resolve full-length DOCK proteins (~180-220 kDa)

  • Load 30-50 μg of total protein per lane

  • Include positive control samples (e.g., SKOV-3 cell lysate)

• Transfer conditions:

  • Use wet transfer at 30V overnight at 4°C for high molecular weight DOCK proteins

  • Select PVDF membranes with 0.45 μm pore size for optimal protein retention

• Antibody incubation:

  • Block with 5% non-fat dry milk in TBS-T for 1 hour at room temperature

  • Dilute DHR2 antibodies 1:1000-1:3000 in blocking buffer

  • Incubate overnight at 4°C with gentle rocking

  • Wash 4 × 5 minutes with TBS-T before secondary antibody incubation

• Detection optimization:

  • For low abundance proteins, consider using enhanced chemiluminescence substrates

  • For quantitative analysis, use fluorescently-labeled secondary antibodies

This protocol has been optimized based on experiences with DOCK protein detection and can be adjusted based on the specific DHR2 antibody characteristics and experimental requirements.

How can immunoprecipitation with DHR2 antibodies be optimized to study protein complexes?

Immunoprecipitation (IP) using DHR2 antibodies requires careful optimization to maintain complex integrity:

• Lysis buffer selection:

  • For stable complexes: use NP-40 buffer (150 mM NaCl, 1% NP-40, 50 mM Tris pH 8.0)

  • For transient interactions: add 0.5-1% digitonin to better preserve membrane protein associations

• Antibody binding:

  • Use 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate

  • Pre-clear lysates with protein A/G beads before adding antibody

  • Incubate with rotation at 4°C for 4-16 hours

• Bead selection and handling:

  • Choose magnetic beads for gentler handling and less non-specific binding

  • Use salmon sperm DNA or BSA pre-blocking for reduced background

  • Perform washing steps at 4°C with ice-cold buffers

• Elution strategies:

  • For western blot: use SDS sample buffer at 70°C for 10 minutes

  • For mass spectrometry: consider peptide elution to reduce antibody contamination

  • For functional assays: use gentle elution with excess immunizing peptide

• Complex verification:

  • Probe for known interaction partners (e.g., ELMO proteins for DOCK DHR2)

  • Include negative controls (non-specific IgG) to rule out non-specific binding

These methodological refinements can significantly improve the specificity and yield of DHR2-containing protein complexes in IP experiments.

How should researchers address common issues with DHR2 antibody specificity?

DHR2 antibody experiments may encounter several specificity challenges that can be methodically addressed:

• Cross-reactivity issues:

  • Perform pre-adsorption of antibody with recombinant proteins from related DOCK family members

  • Include knockout/knockdown controls to confirm band specificity

  • Use domain-specific antibodies targeting unique regions within DHR2

• Background signal:

  • Optimize blocking conditions using different agents (BSA, casein, commercial blockers)

  • Increase washing stringency with higher salt concentrations (up to 500 mM NaCl)

  • Use monovalent Fab fragments instead of whole IgG for reduced non-specific binding

• Inconsistent detection:

  • Verify protein expression conditions that might affect DHR2 domain accessibility

  • Consider fixation methods that may mask or expose different epitopes

  • Test multiple antibodies targeting different regions of the DHR2 domain

• Signal validation strategies:

  • Implement peptide competition assays using the immunizing peptide

  • Compare results from multiple antibodies against the same target

  • Correlate antibody results with mRNA expression data

These approaches form a systematic strategy to address specificity concerns and ensure reliable data interpretation in DHR2 antibody-based experiments.

What approaches can resolve contradictory results when using different DHR2 antibodies?

When different DHR2 antibodies yield contradictory results, researchers should implement a structured analytical approach:

• Epitope mapping:

  • Determine precise epitope locations for each antibody using peptide arrays or deletion constructs

  • Correlate epitope accessibility with protein conformational states

  • Consider post-translational modifications that might affect epitope recognition

• Validation hierarchy:

  • Prioritize results from antibodies validated with genetic knockout controls

  • Compare results with orthogonal detection methods (mass spectrometry, fluorescent tagging)

  • Evaluate antibody performance in multiple experimental systems

• Functional correlation:

  • Determine whether antibody binding affects protein function (GEF activity for DHR2)

  • Correlate antibody detection with functional readouts (RAC1 activation)

  • Consider antibody interference with protein-protein interactions

• Quantitative assessment:

  • Implement titration experiments to determine antibody sensitivity and specificity

  • Use recombinant standards for absolute quantification where possible

  • Apply statistical approaches to evaluate result consistency across experiments

By systematically analyzing these factors, researchers can resolve contradictory results and develop a more complete understanding of DHR2 domain structure and function.

How are AI-based approaches transforming DHR2 antibody design and application?

Recent advances in AI-driven protein design are revolutionizing antibody development, with significant implications for DHR2 antibody research:

The Baker Lab has recently introduced RFdiffusion, an AI system fine-tuned to design human-like antibodies . This technology extends beyond previous capabilities:

• Advanced structural modeling:

  • RFdiffusion can now model flexible antibody loops—crucial for designing antibodies against variable regions of DHR2

  • The system produces antibody designs unlike any seen during training that can bind user-specified targets

  • This capability is particularly valuable for targeting specific conformational states of the DHR2 domain

• From fragments to complete antibodies:

  • Initial AI models could only design short antibody fragments (nanobodies)

  • The updated RFdiffusion can now generate more complete and human-like antibodies called single chain variable fragments (scFvs)

  • This advancement enables development of more versatile DHR2 detection reagents

• Experimental validation:

  • AI-designed antibodies have been successfully tested against disease-relevant targets

  • Similar approaches could be applied to develop antibodies targeting specific epitopes within the DHR2 domain

  • These antibodies could distinguish between different conformational states of DOCK proteins

• Accessibility for researchers:

  • The RFdiffusion software is now free for both non-profit and for-profit research

  • This democratizes access to advanced antibody design tools for DHR2 research

  • Collaborative networks may accelerate development of next-generation DHR2 antibodies

These AI-driven approaches promise to overcome traditional limitations in antibody development, potentially enabling more precise tools for studying DHR2 domain dynamics and interactions.

What novel delivery methods might enhance DHR2 antibody applications in cellular and in vivo systems?

Innovative delivery systems are expanding the potential applications of research antibodies, including those targeting DHR2:

• Supramolecular hydrogel delivery systems:

  • Recent research has developed injectable, subcutaneous depot hydrogels for antibody delivery

  • These polymer-nanoparticle (PNP) hydrogels exhibit shear-thinning and self-healing properties ideal for controlled release

  • For DHR2 antibodies, such systems could enable sustained delivery in experimental models studying DOCK protein function

• Pharmacokinetic optimization:

  • Multi-compartment modeling approaches help predict antibody distribution and clearance

  • This modeling can inform the design of delivery systems to maintain therapeutic concentrations

  • For DHR2 research, optimized delivery could enable long-term studies of DOCK protein inhibition

• Stability enhancements:

  • PNP hydrogels can maintain antibody stability during stressed aging

  • This addresses a major challenge in experimental antibody applications

  • For DHR2 antibodies with limited stability, these approaches could significantly extend usable lifespan

• Translational potential:

  • Optimized delivery systems bridge the gap between in vitro findings and in vivo applications

  • Two-compartment pharmacokinetic models provide a framework for scaling delivery approaches

  • These advances could accelerate translation of DHR2-targeting approaches from cellular systems to animal models

These delivery innovations may enable new experimental paradigms for studying DHR2 function in complex physiological contexts, expanding the utility of existing antibodies beyond conventional applications.